Volume 65, Issue 4, Pages (October 2016)

Slides:

Advertisements

Similar presentations

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.

Global gene repression in hepatocellular carcinoma and fetal liver, and suppression of dudulin-2 mRNA as a possible marker for the cirrhosis-to-tumor transition.

Volume 61, Issue 1, Pages (July 2014)

Volume 63, Issue 1, Pages (July 2015)

Volume 46, Issue 3, Pages (March 2007)

Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen

Volume 42, Issue 4, Pages (April 2005)

Inflammasomes in liver diseases

Masatoshi Kudo Clinical Gastroenterology and Hepatology

Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: A systematic review of the literature Omar Abdel-Rahman,

Volume 56, Issue 4, Pages (April 2012)

Volume 67, Issue 2, Pages (August 2017)

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review Christian Thoma, Christopher P. Day, Michael.

The GAPs between hepatocellular carcinoma and RAS

Global trends and predictions in hepatocellular carcinoma mortality

Coffee Reduces Risk for Hepatocellular Carcinoma: An Updated Meta-analysis Francesca Bravi, Cristina Bosetti, Alessandra Tavani, Silvano Gallus, Carlo.

Volume 68, Issue 5, Pages (May 2018)

Matthew T. Kitson, Stuart K. Roberts Journal of Hepatology

NS5A inhibitors in the treatment of hepatitis C

Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals Liver Cancer - DOI: / Fig. 1. Flowchart of included.

Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis Astrid Marot, Jean Henrion, Jean-François.

Living donor liver transplantation: is the hype over?

The place of downstaging for hepatocellular carcinoma

Volume 58, Issue 3, Pages (March 2013)

Jordan J. Feld, Graham R. Foster Journal of Hepatology

Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw Journal of Hepatology

European Association for the Study of the Liver Journal of Hepatology

Volume 68, Issue 1, Pages (January 2018)

Hepatitis C core protein – The “core” of immune deception?

Volume 61, Issue 1, Pages S108-S119 (November 2014)

Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study Gyuri Kim, Suk-Yong Jang, Chung.

Volume 61, Issue 1, Pages S69-S78 (November 2014)

Why men are at higher risk for hepatocellular carcinoma?

Volume 62, Issue 3, Pages (March 2015)

Genomic risk of hepatitis C-related hepatocellular carcinoma

Darius Moradpour, Arash Grakoui, Michael P. Manns

Autophagy in the liver Journal of Hepatology

Volume 66, Issue 2, Pages (February 2017)

EASL Clinical Practice Guidelines: Wilson’s disease

Economics of chronic hepatitis B and hepatitis C

Preadmission statin use improves the outcome of less severe sepsis patients - a population-based propensity score matched cohort study M.G. Lee, C.-C.

Volume 57, Issue 5, Pages (November 2012)

Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma Tao Jiang, Andrew X. Zhu, Dushyant V. Sahani

Molecular prognostication of liver cancer: End of the beginning

Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong

Paul C. Adams, James C. Barton Journal of Hepatology

Chetana Lim, Chady Salloum, Daniel Azoulay

Evolution of liver transplantation for hepatocellular carcinoma

Clinical Practice Guidelines of the European Association for the study of the Liver – Advancing methodology but preserving practicability Markus Cornberg,

Global burden of alcoholic liver diseases

HCV targeting of patients with cirrhosis

Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma

Volume 63, Issue 1, Pages (July 2015)

Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences Zobair M. Younossi, Aybike Birerdinc,

Chronic hepatitis B in children and adolescents

Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice Paolo Angeli, Pere Gines

Volume 66, Issue 3, Pages (March 2017)

Volume 62, Issue 4, Pages (April 2015)

Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence Christian Toso, Gilles Mentha, Pietro.

Volume 70, Issue 4, Pages (April 2019)

New trials and results in systemic treatment of HCC

Liver transplantation in children

Pathogenesis of cholestatic hepatitis C

Chimeric mouse model of hepatitis B virus infection

The relationship between age and fat infiltration in liver and muscle

Masatoshi Kudo Clinical Gastroenterology and Hepatology

Genetics of hepatocellular carcinoma: The next generation

Partial hepatectomy vs

Reversion of disease manifestations after HCV eradication

Presentation transcript:

Volume 65, Issue 4, Pages 734-740 (October 2016) Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts Journal of Hepatology Volume 65, Issue 4, Pages 734-740 (October 2016) DOI: 10.1016/j.jhep.2016.05.045 Copyright © 2016 Terms and Conditions

Journal of Hepatology 2016 65, 734-740DOI: (10. 1016/j. jhep. 2016. 05 Copyright © 2016 Terms and Conditions

Fig. 1 Flow-chart of the 3 multicentre prospective ANRS cohorts. (A) ANRS CO22 HEPATHER. (B) ARNS CO12 CirVir. (C) ARNS CO23 CUPILT. Journal of Hepatology 2016 65, 734-740DOI: (10.1016/j.jhep.2016.05.045) Copyright © 2016 Terms and Conditions

Fig. 2 Recurrence of HCC according to DAA treatment in the ANRS CO22 HEPATHER cohort. Pseudo-survival curves were plotted for time-dependent DAA treatment. Journal of Hepatology 2016 65, 734-740DOI: (10.1016/j.jhep.2016.05.045) Copyright © 2016 Terms and Conditions